Volume 25 Issue 12, December 2019
Comment | 25 November 2019
Benefit Corporation: a path to affordable gene therapies?
With the growing number of efficient gene therapies on the market, now is the time to take actions to ensure reasonable pricing of gene therapy products. Among these, we propose to incentivize gene therapy companies to adopt a status that translates their corporate social responsibility into concrete commitments.
Alain Fischer, Mathias Dewatripont & Michel Goldman